Teva's biosimilar rituximab 'still active'
This article was originally published in Scrip
Executive Summary
Teva Pharmaceuticals' biosimilar rituximab progam has not been terminated, or at least not yet. The generics giant told Scrip that it has "no new updates on rituximab, the project is active".